Clinical Trial Details
TOMMORROW Study Official Title:
A double-blind, randomized, placebo-controlled, parallel group study to simultaneously qualify a biomarker algorithm for prognosis of risk of developing mild cognitive impairment due to Alzheimer's disease (MCI due to AD) and to test the efficacy of pioglitazone to delay the onset of MCI due to AD in cognitively normal subjects.
Start Date January 10, 2014
End Date July 10, 2014
| Gender Preference |
|None|| Age Group |
|65 - 83 years|
| Principal Investigator |
|Jennifer Robinson, MD, MPH|
| Contact Info |
Study Coordinator: Erin Balkenende 319-353-8233 (email@example.com)
Principal Investigator: 319-384-5030 (firstname.lastname@example.org)
|CPH/Dept. of Epidemiology|
The Preventive Intervention Center at the University of Iowa is conducting a study to find out if a new test can predict who may develop cognitive problems due to Alzheimer's disease based on their genes. This research will also test an investigational medication to see if it can delay the symptoms of cognitive disorders.
Adults aged 65-83 may qualify to participate in this study.
Eligible participants receive at no cost:
Memory and thinking evaluations
You may receive compensation for time and travel. The study will last about 5 years and include 5 clinic visits the first year, then 2 visits a year until the end of the study.
To learn more, email us at email@example.com or call 319/353-8233 or 1-800/887-6917.
|aging ; Alzheimer ; cognitive health ; dementia ; memory ; older adults ; seniors ; |